$SERA
Sera Prognostics, Inc. Class A Common Stock
XNAS•Health Care•Services-Medical Laboratories
Why is SERA up today? It is at $2.14 (+1.90%). See the catalyst behind the move, real-time alerts the moment SERA spikes, and full due diligence on SERA — key stats, earnings, dilution and insider activity. Free.
Get free $SERA alerts the moment volume spikes
Be first to know when $SERA makes an unusual move. Create a free account to track $SERA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $2.14
- Change today
- +1.90%
- Previous close
- $2.10
- 52-week range
- $1.56 – $3.95
- Market cap
- $84M
- Institutional own.
- 47.58%
- Total held
- 59.7%
- Tradeable float
- 15.8M 40% of shares · after 12% insiders + 48% institutions
- Short interest
- 231K ▼ -4% vs prior · as of 2026-07-31
- Short % of float
- 1.5%
- Days to cover
- 6.4d
- Avg daily volume
- 55K
- Sector
- Health Care
- Industry
- Services-Medical Laboratories
- Exchange
- XNAS
- 5m
- 0.3x
- 15mthin
- 0.1x
- 1hthin
- 0.1x
- 1D
- --
Get free SERA + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $SERA up today?
Here is the latest on SERA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for SERA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystSalt Lake City – August 19, 2026 – Sera Prognostics Inc., The PregnancyReported prematurity in the United States were estimated to be approximately $25 billion for 2016., from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
Insiders buying9 buys, 8 sells last 3 months (16/62 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Barlow Jane F Director | Acquired (grant/award) | +24K 0.06% of company | added 100% | 47K | n/a | Jul 10, 26 |
Capone Mark Christopher Director | Acquired (grant/award) | +44K 0.1% of company | n/a | 44K | n/a | Jul 10, 26 |
Critchfield Gregory C Director | Acquired (grant/award) | +24K 0.06% of company | added 2.9% | 847K | n/a | Jul 10, 26 |
Kamdar Kim P. Director | Acquired (grant/award) | +26K 0.07% of company | added 79% | 58K | n/a | Jul 10, 26 |
Lawrence Sandra Aj Director | Acquired (grant/award) | +25K 0.06% of company | added 100% | 41K | n/a | Jul 10, 26 |
Mirza Mansoor Raza Director | Acquired (grant/award) | +24K 0.06% of company | added 42% | 82K | n/a | Jul 10, 26 |
Phillips Joshua Director | Acquired (grant/award) | +25K 0.06% of company | added 43% | 82K | n/a | Jul 10, 26 |
Jackson Benjamin Officer | Sold (automatic/other) | -2K | sold 1.3% | 162K | $4K at $2.01 | Jun 11, 26 |
Lindgardt Zhenya Officer | Sold (automatic/other) | -7K 0.02% of company | sold 0.8% | 865K | $14K at $2.01 | Jun 11, 26 |
Inglis Tiffany Eul Davis Officer | Sold (automatic/other) | -362 | sold 0.4% | 92K | $728 at $2.01 | Jun 11, 26 |
Aerts Austin Officer | Sold (automatic/other) | -2K | sold 0.7% | 301K | $4K at $2.01 | Jun 11, 26 |
Anderson Dyaarl Lee Jr. Officer | Sold (automatic/other) | -5K 0.01% of company | sold 5.7% | 78K | $10K at $2.01 | Jun 11, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringAt-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $SERA runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- 19,900,498 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $40.0M in size · Priced at $2.01/share
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$SERA Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$SERA Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Stocks similar to SERA
Comparable names in services-medical laboratories, closest in size first.
SERA stock FAQ
Why is $SERA up today?
Here is the latest on SERA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for SERA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
What is the SERA stock price today?
SERA last traded at $2.14, up 1.90% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live SERA alerts?
The SERA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged SERA 0 times in the last 30 days.
What exchange is SERA on?
SERA (Sera Prognostics, Inc. Class A Common Stock) trades on XNAS, with a market cap of about $84M in the SERVICES-MEDICAL LABORATORIES sector.
Is SERA good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge SERA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.